An observational study in Placenta Accreta Spectrum and Placenta Previa, sponsored by Adana City Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Adana City Training and Research Hospital · Observational
Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion.
Methods:
This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.
150 studies on the registry are indexed under Placenta Accreta; 40 are open to participants now.
This study's enrollment of 84 is close to the median of 87 across 78 observational studies indexed under Placenta Accreta.
Browse Placenta Accreta studies →Adana City Training and Research Hospital is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Pregnant women aged 18-45 years in the reproductive period with singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS were included in the study. The control group consisted of healthy pregnant women in the third trimester with similar demographic characteristics who underwent elective cesarean delivery and had no obstetric or medical comorbidities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant women aged 18-45 years viable third-trimester pregnancies diagnosed with placenta previa and/or PAS (Placenta accreta spectrum)
healthy pregnant women in the third trimester with similar demographic characteristics
Blood serum Adropin levels
The aim of the present study was to evaluate maternal serum adropin levels in pregnancies complicated by placenta previa and placenta accreta spectrum and compare to healthy controls.
Time frame: From 15.04.2024 to 01.04.2025
Plan to share: No — Demographical values could be shared. The questionaries answers are personal so only scale results may be shown.
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adana City Training and Research Hospital